Home
Laboratory Diagnostics
Molecular Diagnostics
Molecular Diagnostics Assays and Reagent Kits
VERSANT HCV Genotype 2.0 Assay (LiPA)

VERSANT HCV Genotype 2.0 Assay (LiPA)

Highly Accurate HCV Genotype and Subtype Detection

The VERSANT^® HCV Genotype 2.0 Assay (LiPA)* utilizes the trusted reverse-hybridization technology to detect genotypes 1-6 and subtypes 1a and 1b. This assay is used with the Auto-LiPA 48 and AutoBlot 3000H automated systems to provide highly accurate identification of HCV genotypes and subtypes for optimal patient therapy.

Proven Reliability
Total Genotyping Solution

Features & Benefits

Perform HCV Genotyping and Subtyping with Greater Accuracy

The VERSANT HCV Genotype 2.0 Assay (LiPA)* uses the trusted reverse-hybridization technology to provide accurate identification of HCV genotype and subtype specific data for optimal patient therapy.

Subtype Information

Highly accurate differentiation of subtypes 1a vs.1b showing more than 98% concordance with NS5B sequencing
Increased genotyping and subtyping accuracy due to dual target analysis of 5’ non coding and core viral genomic regions

Proven Reliability

Most widely used HCV genotyping assay
Trusted reverse-hybridization technology (LiPA)
Validated with NS5B sequencing

Total Genotyping Solution

Full integration from extraction to automated interpretation
Minimal hands-on time as most manual steps are automated with the Auto-LiPA 48 or AutoBlot 3000H systems

Customer Testimonial

“The determination of hepatitis C virus (HCV) genotype is mandatory to tailor peginterferon-ribavirin treatment dose and duration. Subtype determination is likely to become useful to tailor specific HCV inhibitor therapy and interpret resistance profiles in the near future. The new VERSANT Genotype Assay (LiPA), a second generation line probe assay, contains probes targeting both the 5’ non coding and the core regions of the viral genome. This has improved the accuracy of HCV genotype 1 subtype determination, particularly discrimination between subtypes 1a and 1b, the most frequent HCV subtypes in clinical practice. The assay also displays improved discrimination among HCV genotypes 1 and 6 relative to the previous version. Only 4% of clinical specimens are mistyped with the VERSANT Genotype Assay relative to the reference method (direct sequence analysis of the NS5B region), which makes it the most accurate method for use in clinical practice. The assay is user-friendly and provides quick results.”

Stèphane Chevaliez
Assistant Hospitalier Universitaire
Centre National de Référence des Hépatites B, C et delta
Laboratoire de Virologie et Inserm U841
Hospital Henri Mondor
Universite Paris XII
94010 CRETEIL, FRANCE

Technical Details

Ordering Information
Systems	Catalog No.	Product	No. of Tests
	10313066	Auto-LiPA 48 Genotyping Instrument	48 Tests/Run
	10315618	AutoBlot 3000H Genotyping Instrument	20 Tests/Run
	10282928	VERSANT kPCR Sample Prep	1 Unit
	10702391	VERSANT kPCR SP Workstation Kit	1 Unit
Reagents	10492004	VERSANT HCV Genotype 2.0 Assay	40 Tests
	10492005	VERSANT HCV Genotype 2.0 Assay	100 Tests
	10719666	VERSANT HCV Amplification 2.0 Kit	40 Tests
	10719667	VERSANT HCV Amplification 2.0 Kit	100 Tests
	10719668	VERSANT HCV Control 2.0 Kit	6 Tests
Software and Scanner	10492006	LiPA - Scan HCV IVD Software V1.00	1 Unit
	10817497	LiPA SP 2.0 Software Installation Kit	1 Unit
	10322207	Scanner, LiPA-Scan-verified (110 V)	1 Unit

LiPA Consumables
10325628	Auto-LiPA 48 Strips Tray (25 per set)
10315381	AutoBlot 3000 Strips Tray (25 per set)
10329226	VERSANT LiPA Scan Reading Template (25 templates)

Services & Support Education & Training

Did this information help you?

*LiPA is FDA-approved for IVD use in the U.S.

VERSANT is a registered trademark of Siemens. All other marks are the property of their respective owners.

The VERSANT HCV Genotype 2.0 Assay (LiPA) is a line probe assay, for in vitro diagnostic use, which identifies Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes 1a and 1b in human serum or plasma (K2EDTA, ACD-A CPD, and CPDA) samples. The VERSANT HCV Genotype 2.0 Assay (LiPA) is intended to be used as an aid in the management of patients with chronic HCV infection to guide the selection of antiviral treatment. The VERSANT HCV Genotype 2.0 Assay (LiPA) is not approved for use as a donor screening test for HCV or as a diagnostic test to confirm the presence of HCV.